|
1
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coates AS, Winer EP, Goldhirsch A, Gelber
RD, Gnant M, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel
Members: Tailoring therapies-improving the management of early
breast cancer: St Gallen international expert consensus on the
primary therapy of early breast cancer 2015. Ann Oncol.
26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Emery P, Durand B, Mach B and Reith W: RFX
proteins, a novel family of DNA binding proteins conserved in the
eukaryotic kingdom. Nucleic Acids Res. 24:803–807. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohashi Y, Ueda M, Kawase T, Kawakami Y and
Toda M: Identification of an epigenetically silenced gene, RFX1, in
human glioma cells using restriction landmark genomic scanning.
Oncogene. 23:7772–7779. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Feng C, Zhang Y, Yin J, Li J, Abounader R
and Zuo Z: Regulatory factor X1 is a new tumor suppressive
transcription factor that acts via direct downregulation of CD44 in
glioblastoma. Neuro Oncol. 16:1078–1085. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Su JC, Tseng PH, Hsu CY, Tai WT, Huang JW,
Ko CH, Lin MW, Liu CY, Chen KF and Shiau CW: RFX1-dependent
activation of SHP-1 induces autophagy by a novel obatoclax
derivative in hepatocellular carcinoma cells. Oncotarget.
5:4909–4919. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen L, Smith L, Johnson MR, Wang K,
Diasio RB and Smith JB: Activation of protein kinase C induces
nuclear translocation of RFX1 and down-regulates c-myc via an
intron 1 X box in undifferentiated leukemia HL-60 cells. J Biol
Chem. 275:32227–32233. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kanda M, Shimizu D, Fujii T, Tanaka H,
Shibata M, Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, et
al: Protein arginine methyltransferase 5 is associated with
malignant phenotype and peritoneal metastasis in gastric cancer.
Int J Oncol. 49:1195–1202. 2016.PubMed/NCBI
|
|
10
|
Kanda M, Shimizu D, Nomoto S, Takami H,
Hibino S, Oya H, Hashimoto R, Suenaga M, Inokawa Y, Kobayashi D, et
al: Prognostic impact of expression and methylation status of
DENN/MADD domain-containing protein 2D in gastric cancer. Gastric
Cancer. 18:288–296. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kanda M, Nomoto S, Oya H, Takami H,
Shimizu D, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S,
et al: The expression of melanoma-associated antigen D2 both in
surgically resected and serum samples serves as clinically relevant
biomarker of gastric cancer progression. Ann Surg Oncol. 23:(Suppl
2). S214–S221. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanda M, Shimizu D, Fujii T, Sueoka S,
Tanaka Y, Ezaka K, Takami H, Tanaka H, Hashimoto R, Iwata N, et al:
Function and diagnostic value of Anosmin-1 in gastric cancer
progression. Int J Cancer. 138:721–730. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takai D and Jones PA: Comprehensive
analysis of CpG islands in human chromosomes 21 and 22. Proc Natl
Acad Sci USA. 99:3740–3745. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li LC and Dahiya R: MethPrimer: Designing
primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kanda M, Shimizu D, Tanaka H, Shibata M,
Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, Fujii T, et
al: Metastatic pathway-specific transcriptome analysis identifies
MFSD4 as a putative tumor suppressor and biomarker for hepatic
metastasis in patients with gastric cancer. Oncotarget.
7:13667–13679. 2016.PubMed/NCBI
|
|
16
|
Finn RS, Dering J, Conklin D, Kalous O,
Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al: PD
0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially
inhibits proliferation of luminal estrogen receptor-positive human
breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Subik K, Lee JF, Baxter L, Strzepek T,
Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG and
Tang P: The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67
and AR by immunohistochemical analysis in breast cancer cell lines.
Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBI
|
|
18
|
Gajiwala KS, Chen H, Cornille F, Roques
BP, Reith W, Mach B and Burley SK: Structure of the winged-helix
protein hRFX1 reveals a new mode of DNA binding. Nature.
403:916–921. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reith W, Ucla C, Barras E, Gaud A, Durand
B, Herrero-Sanchez C, Kobr M and Mach B: Rfx1, A transactivator of
hepatitis-B virus enhancer-I, belongs to a novel family of
homodimeric and heterodimeric DNA-binding proteins. Mol Cell Biol.
14:1230–1244. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Katan-Khaykovich Y, Spiegel I and Shaul Y:
The dimerization/repression domain of RFX1 is related to a
conserved region of its yeast homologues Crt1 and Sak1: A new
function for an ancient motif. J Mol Biol. 294:121–137. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sengupta PK, Smith EM, Kim K, Murnane MJ
and Smith BD: DNA hypermethylation near the transcription start
site of collagen alpha2(I) gene occurs in both cancer cell lines
and primary colorectal cancers. Cancer Res. 63:1789–1797.
2003.PubMed/NCBI
|
|
22
|
Watts JA, Zhang C, Klein-Szanto AJ,
Kormish JD, Fu J, Zhang MQ and Zaret KS: Study of FoxA pioneer
factor at silent genes reveals Rfx-repressed enhancer at Cdx2 and a
potential indicator of esophageal adenocarcinoma development. PLoS
Genet. 7:e10022772011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rauscher GH, Kresovich JK, Poulin M, Yan
L, Macias V, Mahmoud AM, Al-Alem U, Kajdacsy-Balla A, Wiley EL,
Tonetti D and Ehrlich M: Exploring DNA methylation changes in
promoter, intragenic, and intergenic regions as early and late
events in breast cancer formation. BMC Cancer. 15:8162015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang X, Han H, De Carvalho DD, Lay FD,
Jones PA and Liang G: Gene body methylation can alter gene
expression and is a therapeutic target in cancer. Cancer Cell.
26:577–590. 2014. View Article : Google Scholar : PubMed/NCBI
|
